- Home
- JMM vs ITRM Comparison
JMM vs ITRM Comparison
Compare JMM & ITRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JMM
- ITRM
- Stock Information
- Founded
- JMM 1988
- ITRM 2015
- Country
- JMM United States
- ITRM Ireland
- Employees
- JMM N/A
- ITRM N/A
- Industry
- JMM Trusts Except Educational Religious and Charitable
- ITRM Biotechnology: Pharmaceutical Preparations
- Sector
- JMM Finance
- ITRM Health Care
- Exchange
- JMM Nasdaq
- ITRM Nasdaq
- Market Cap
- JMM 56.8M
- ITRM 49.5M
- IPO Year
- JMM N/A
- ITRM 2018
- Fundamental
- Price
- JMM $5.98
- ITRM $1.54
- Analyst Decision
- JMM
- ITRM Strong Buy
- Analyst Count
- JMM 0
- ITRM 1
- Target Price
- JMM N/A
- ITRM $5.00
- AVG Volume (30 Days)
- JMM 16.1K
- ITRM 671.4K
- Earning Date
- JMM 01-01-0001
- ITRM 11-14-2024
- Dividend Yield
- JMM 5.44%
- ITRM N/A
- EPS Growth
- JMM N/A
- ITRM N/A
- EPS
- JMM N/A
- ITRM N/A
- Revenue
- JMM N/A
- ITRM N/A
- Revenue This Year
- JMM N/A
- ITRM N/A
- Revenue Next Year
- JMM N/A
- ITRM N/A
- P/E Ratio
- JMM N/A
- ITRM N/A
- Revenue Growth
- JMM N/A
- ITRM N/A
- 52 Week Low
- JMM $5.29
- ITRM $0.81
- 52 Week High
- JMM $6.10
- ITRM $3.02
- Technical
- Relative Strength Index (RSI)
- JMM 43.26
- ITRM 39.39
- Support Level
- JMM $5.97
- ITRM $1.58
- Resistance Level
- JMM $6.14
- ITRM $2.10
- Average True Range (ATR)
- JMM 0.08
- ITRM 0.14
- MACD
- JMM -0.00
- ITRM -0.04
- Stochastic Oscillator
- JMM 30.43
- ITRM 11.11
About JMM Nuveen Multi-Market Income Fund (MA)
Nuveen Multi-Market Income Fund is a United States-based closed-end management investment company. The investment objective of the company is to provide high monthly income consistent with prudent risk to capital. The fund predominantly invests in debt securities including, but not limited to residential and commercial mortgage-backed securities, asset-backed securities, corporate debt obligations, convertible debt securities, U.S. government securities, and other such fixed income instruments. It may also invest in preferred stocks.
About ITRM Iterum Therapeutics plc
Iterum Therapeutics PLC is a clinical-stage pharmaceutical company. The company is engaged in developing and commercializing sulopenem to be the first and only oral and intravenous branded penem available globally. Its sulopenem program has the potential to offer a solution to the problem of antibiotic resistance and the toxicity limitations of existing agents. The company operates as a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.